News and Trends 30 Apr 2018 Record Series B Financing Supports Antibody Cancer Therapy …of antibody-based therapies for cancer has recently been on the rise in European biotech. For example, late last year Argenx raised €195M to support the clinical development of its antibody… April 30, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2020 Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle Update (04/06/2020): After upholding four of Kymab’s patents addressing the production of antibody drugs earlier this year, the US Patent Trial and Appeal Board has rejected Regeneron’s attempt to invalidate… June 4, 2020 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 German Biotech Enters the Clinic with Next-Generation Antibody for AML …immunotherapy candidate, TacSyn, to treat patients at a stage of existing disease of AML as well as acute lymphoblastic leukemia (ALL). This bispecific antibody contains an anti-CD3 domain, which is… May 31, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2017 The EU Approves New Treatment for a Rare Pediatric Cancer …Human Use (CHMP) has now given a positive opinion on APN311, recommending the approval of the new drug. APN311 is a monoclonal antibody targeting the neuroblastoma-specific antigen GD2. The antibody… May 8, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2016 UK Upstart to sign Huge Deal with Takeda in End Run around Antibody Therapies …unabridged antibody counterparts, almost comparable to small peptides. Figure 1. A diagram of a whole antibody – Humabodies whittle these down to just the VH domain reflecting the antibody binding… October 11, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 12 Feb 2018 MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert …those compounds,” he continued. MorphoSys’ first attempt at taking its own antibody to market will be with its blood cancer candidate, MOR208, a monoclonal antibody that targets CD19, which is… February 12, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2017 Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that… July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2023 Epsilogen completes first clinical trial of IgE antibody to treat cancer …results were published in Nature Communications. MOv18 IgE is Epsilogen’s lead IgE antibody drug candidate and binds to anti-folate receptor (FRα), a well validated target for ovarian cancer. It was… July 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 Next-Gen Cancer Antibody Technology from Germany enters the Clinic Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie… April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2025 ASCO 2025: key highlights in cancer therapeutics …candidate is also in the clinic for cervical cancer. Another clinical-stage biotech that unveiled data from its cancer immunotherapy trial is Paris-based Enterome. Its candidate EO4010 is made up of… June 4, 2025 - 18 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2017 What Cancer Therapies did European Biotechs Showcase at ASCO 2017? …competitors, BMS, MSD and Roche, in the coveted PD-L1 / PD-1 checkpoint inhibitor space. The Danish antibody giant Genmab presented a Phase I/IIa update on HuMax-AXL-ADC, an antibody-drug conjugate (ADC)… June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Dec 2021 The Billion-Euro European Biotech Companies in 2022 …of antibody treatments for cancer and inflammatory and autoimmune diseases. Its first antibody, Tremfya, a treatment for psoriasis, was launched in 2017 in collaboration with Janssen. The company has ongoing… December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email